Patents by Inventor Patrick R. Verhoest
Patrick R. Verhoest has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8598200Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.Type: GrantFiled: November 30, 2011Date of Patent: December 3, 2013Assignee: Pfizer Inc.Inventors: Amy B Dounay, Laura McAllister, Vinod D Parikh, Suobao Rong, Patrick R Verhoest
-
Patent number: 8487104Abstract: The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3, 4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.Type: GrantFiled: November 30, 2011Date of Patent: July 16, 2013Assignee: Pfizer Inc.Inventors: Amy B Dounay, Christopher J Helal, Jamison B Tuttle, Patrick R Verhoest
-
Publication number: 20120302599Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.Type: ApplicationFiled: November 30, 2011Publication date: November 29, 2012Inventors: Amy B. Dounay, Laura McAllister, Vinod D. Parikh, Suobao Rong, Patrick R. Verhoest
-
Patent number: 8278295Abstract: The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.Type: GrantFiled: January 26, 2010Date of Patent: October 2, 2012Assignee: Pfizer Inc.Inventors: Michelle M. Claffey, Christopher J. Helal, Patrick R. Verhoest
-
Publication number: 20120142729Abstract: The present invention relates to compounds 3-amino-1-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline-7-carbonitrile, 3-amino-1-hydroxy-7-(2-methoxyethoxy)-3,4-dihydroquinolin-2(1H)-one, and 3-amino-1-hydroxy-7-[(1S)-2-methoxy-1-methylethoxy]-3,4-dihydroquinolin-2(1H)-one, including racemic mixtures and resolved enantiomers thereof, to pharmaceutically acceptable salts thereof, and to the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.Type: ApplicationFiled: November 30, 2011Publication date: June 7, 2012Inventors: AMY B. DOUNAY, Christopher J. Helal, Jamison B. Tuttle, Patrick R. Verhoest
-
Patent number: 8183238Abstract: Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.Type: GrantFiled: June 16, 2010Date of Patent: May 22, 2012Assignee: Pfizer Inc.Inventors: Michelle M. Claffey, Amy B. Dounay, Matthew M. Hayward, Suobao Rong, Patrick R. Verhoest, Jamison B. Tuttle, Xinmin Gan
-
Publication number: 20100324043Abstract: Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.Type: ApplicationFiled: June 16, 2010Publication date: December 23, 2010Inventors: Michelle M. Claffey, Amy B. Dounay, Matthew M. Hayward, Suobao Rong, Patrick R. Verhoest, Jamison B. Tuttle, Xinmin Gan
-
Patent number: 7825254Abstract: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.Type: GrantFiled: February 27, 2008Date of Patent: November 2, 2010Assignee: Pfizer Inc.Inventors: Patrick R. Verhoest, Christopher J. Helal, Dennis J. Hoover, John M. Humphrey
-
Publication number: 20100190771Abstract: The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Inventors: Michelle M. Claffey, Christopher J. Helal, Patrick R. Verhoest
-
Publication number: 20090030003Abstract: The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.Type: ApplicationFiled: May 9, 2008Publication date: January 29, 2009Inventors: Patrick R. Verhoest, Caroline Proulx-Lafrance
-
Patent number: 7429665Abstract: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.Type: GrantFiled: January 5, 2006Date of Patent: September 30, 2008Assignee: Pfizer IncInventors: Patrick R. Verhoest, Christopher J. Helal, Dennis J. Hoover, John M. Humphrey
-
Publication number: 20080214607Abstract: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.Type: ApplicationFiled: February 27, 2008Publication date: September 4, 2008Inventors: Patrick R. Verhoest, Christopher J. Helal, Dennis J. Hoover, John M. Humphrey
-
Patent number: 7250418Abstract: The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF1 receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF1 receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF1 receptors.Type: GrantFiled: May 6, 2004Date of Patent: July 31, 2007Assignee: Pfizer IncInventors: Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman, Patrick R. Verhoest
-
Patent number: 7087617Abstract: This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.Type: GrantFiled: May 5, 2004Date of Patent: August 8, 2006Assignee: Pfizer Inc.Inventors: Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman, Patrick R. Verhoest
-
Patent number: 7041672Abstract: Substituted aryl pyrazine derivatives of the formula I as defined herein, and their use in treating anxiety disorders, depression and stress related disorders are disclosed.Type: GrantFiled: May 12, 2004Date of Patent: May 9, 2006Assignee: Pfizer Inc.Inventors: Patrick R. Verhoest, Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman
-
Patent number: 7015229Abstract: This invention relates to substituted pyrimidinone and pyrimidithione derivatives that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.Type: GrantFiled: February 20, 2003Date of Patent: March 21, 2006Assignee: Pfizer IncInventors: Jian-Min Fu, Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Robert Louis Hoffman, Patrick R. Verhoest
-
Patent number: 6992087Abstract: Substituted aryl 1,4-pyrazine derivatives of formula I as defined herein and their use in treating anxiety disorders, depression and stress related disorders are disclosed.Type: GrantFiled: November 15, 2002Date of Patent: January 31, 2006Assignee: Pfizer IncInventors: Patrick R. Verhoest, Robert Louis Hoffman, Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu
-
Patent number: 6964965Abstract: The present invention provides substituted pyrazine derivatives of Formula I, that are CRF1 receptor antagonists, including human CRF1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.Type: GrantFiled: April 17, 2003Date of Patent: November 15, 2005Assignee: Pharmacia & UpjohnInventors: Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman, Patrick R. Verhoest
-
Publication number: 20040116444Abstract: Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.Type: ApplicationFiled: August 27, 2003Publication date: June 17, 2004Inventors: Jeffrey W. Corbett, Jian-Min Fu, Michael Dalton Ennis, Kristine E. Frank, Robert Louis Hoffman, Patrick R. Verhoest
-
Publication number: 20040053941Abstract: The present invention provides substituted pyrazine derivatives of Formula I, 1Type: ApplicationFiled: April 17, 2003Publication date: March 18, 2004Inventors: Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman, Patrick R. Verhoest